Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Associations of Mid- and Late-Life Physical Activities With New-Onset Depression and Anxiety Among Older Adults
Syrjanen, Jeremy A. , Kremers, Walter K. , Barisch‐Fritz, Bettina , Krafft, Jelena , Johnson, DeJarra, Fields, Julie A. , Petersen, Ronald , Vassilaki, Maria , Geda, Yonas E., Krell-Roesch, Janina, Barisch-Fritz, Bettina, Wöll, Alexander , Kremers, Walter K , Krell‐Roesch, Janina , Johnson, DeJarra

The Journal of Neuropsychiatry and Clinical Neurosciences | April 28, 2025 | Volume: 38 | Issue: 1 | Pages: 76-83

10.1176/appi.neuropsych.20240255 | PMID 40289590 Get It

Delirium prevalence, interventions and barriers in intensive care units in German‐speaking countries: A retrospective cross‐sectional secondary analysis
Exl, Matthias Thomas , Fischbacher, Sibylle, Liu, Keibun , Hoffmann, Magdalena , Nydahl, Peter, Haken, Rebecca von , Schimböck, Florian , Group, the WDAD Study, Olotu, Cynthia , Jeitziner, Marie-Madlen , Lindroth, Heidi , Jeitziner, Marie‐Madlen , Nydahl, Peter , Krüger, Lars , Group, the WDAD Study

Nursing in Critical Care | April 28, 2025 | Volume: 30 | Issue: 3 | Pages: No page available

10.1111/nicc.70041 | PMID 40289504 Get It

Abstract Background The prevalence of delirium in intensive care units (ICUs) is high and has a major impact on patient outcomes. Aim To describe delirium assessment instruments, prevalence, interventions and barriers in delirium management in adult and paediatric ICUs; and to explore the association between delirium prevalence and reported interventions and barriers at unit level. Study Design A secondary analysis of the cross‐sectional World Delirium Awareness Day Delirium Survey on 15 March 2023. This was a prospective study to assess the one‐day point delirium prevalence, practices and quality improvement efforts across healthcare systems. Data was analysed descriptively and using multiple linear regression. Results Data of 1612 assessments in 123 ICUs from three German‐speaking countries were analysed. The most frequently used delirium assessment instrument was the Intensive Care Delirium Screening Checklist (43.9%, n = 54). The prevalence of delirium at 8 AM was 18.6% and at 8 PM 20.4% from the 94 ICUs included in the regression analyses. Prevalence for adult and paediatric and mixed ICUs are comparable. Main reported over all unit‐level interventions were ‘pain management’ (95.9%, n = 118), ‘mobilization’ (94.3%, n = 116) and ‘verbal re‐orientation’ (84.6%, n = 104). Main reported over all unit‐level barriers were ‘shortage of staff’ (53.7%, n = 66) and ‘patients who are difficult to assess’ (44.7%, n = 55). Interventions such as ‘avoidance of bladder tubes/catheters’ in all ICUs, ‘use of ear plugs and/or sleep glasses’ in adult ICUs and ‘mobilization’ in paediatric and mixed ICUs were associated with reduced delirium prevalence. Across all ICUs, as well as in both adult and paediatric ICUs, ‘lack of appropriate scores for delirium assessment’ was identified as a significant barrier. Conclusions One fifth of assessed ICU patients suffer from delirium. Several reported unit‐level interventions and barriers may have an impact on delirium prevalence, suggesting an approach for future studies and clinical practice. Relevance to Clinical Practice In clinical practice, unit‐level ‘avoidance of bladder tubes/catheters’, ‘use of ear plugs and/or sleep glasses’ and ‘mobilization’ may be used as delirium prevention and treatment interventions.
Increased Risk of Cardiovascular Diseases in Patients With Chronic Hypoparathyroidism in Sweden
Björnsdóttir, Sigríður , Kämpe, Olle , Savarese, Gianluigi , Mannstadt, Michael , Clarke, Bart, Kämpe, Olle , Mannstadt, Michael , Clarke, B.L. , Spelman, Tim D.

The Journal of Clinical Endocrinology & Metabolism | April 27, 2025 | Volume: 110 | Issue: 12 | Pages: e4004-e4010

10.1210/clinem/dgaf257 | PMID 40294163 Get It

Abstract Context Data on cardiovascular outcomes in patients with chronic hypoparathyroidism (hypoPT) are limited. Objective To investigate the risk of cardiovascular outcomes, acute myocardial infarction, atrial fibrillation/flutter, heart failure, valvular heart disease, peripheral artery disease, and stroke/transient ischemic attack (TIA) in patients with chronic hypoPT. Design The Swedish National Patient Registry, the Swedish Prescribed Drug Registry, and the Total Population Registry, 1997-2018. Settings Population-based cohort study in Sweden. Patients National registries were used to identify patients with chronic hypoPT and matched controls. Results A total of 1982 with chronic hypoPT and 19 499 controls were included. After adjustment for cardiovascular risk factors, patients with chronic hypoPT had higher risk of valvular heart disease [hazard ratio (HR) 2.08; 95% confidence interval (CI) 1.67-2.60], peripheral artery disease (HR 1.78; 95% CI 1.41-2.26), heart failure (HR 1.66; 95% CI 1.44-1.90), atrial fibrillation/flutter (HR 1.58; 95% CI 1.38-1.81), acute myocardial infarction (HR 1.31; 95% CI 1.05-1.64), and fatal cardiovascular disease (HR 1.59; 95% CI 1.40-1.80) compared to matched controls. No significant difference in risk of stroke/TIA was observed. Cardiovascular outcomes did not differ between patients with surgical and nonsurgical chronic hypoPT. Females with hypoPT had a significantly increased risk of valvular heart disease, peripheral artery disease, heart failure, atrial fibrillation, myocardial infarction, and fatal cardiovascular disease compared to female controls. There were no differences in any cardiovascular outcomes between males with hypoPT and male controls. Conclusion The risk of cardiovascular diseases was increased in patients with chronic hypoPT, particularly among women. These findings highlight the need for close monitoring and preventive management of cardiovascular risk factors, especially in women.
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis
Mee, Xuan Ci , Lim, Ghee Kheng, Ibrahim, Ramzi , Abdelnabi, Mahmoud , Allam, Mohamed , Bcharah, George , Barry, Timothy, Ayoub, Chadi , Arsanjani, Reza, Ci Mee, Xuan, Kheng Lim, Ghee, Allam, Mohamed N , Tan, Min Choon , Ayoub, Chadi , Ibrahim, Ramzi , Lim, Ghee Kheng, Pham, Hoang Nhat , Farina, Juan M. , Arsanjani, Reza , Lee, Kwan

European Heart Journal - Cardiovascular Pharmacotherapy | April 26, 2025 | Volume: 11 | Issue: 4 | Pages: 334-342

10.1093/ehjcvp/pvaf026 | PMID 40285691 Get It

Abstract Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve heart failure (HF) outcomes but their effects on acute myocardial infarction (AMI) remain poorly characterized. This study aimed to evaluate the 1-year cardiovascular outcomes of SGLT2-Is among patients with AMI. Methods and results We conducted an observational, retrospective cohort study using TriNetX data, including patients aged ≥18 with AMI identified via ICD-10 codes regardless of left ventricular ejection fraction (LVEF), categorized by SGLT2-Is use. Propensity score matching (PSM) was performed to balance baseline demographics, comorbidities, and medication use. Adjusted odds ratios (aORs) were estimated for the primary outcome (recurrent AMI) and the secondary outcomes (acute HF hospitalizations, stroke, all-cause hospitalizations, all-cause mortality, new-onset atrial fibrillation, and cardiac arrest). After PSM, 89 554 patients were analysed (44 777 SGLT2-Is users; 44 777 non-users). The mean age was ∼68 years in both cohorts with a similarly high burden of cardiovascular comorbidities. Mean follow-up duration was 290.854 days for SGLT2-Is users and 284.465 days for non-users. SGLT2-Is use was linked to lower rates of recurrent AMI [aOR: 0.459; 95% confidence interval (CI): 0.367–0.551], all-cause hospitalizations (aOR: 0.782; 95% CI: 0.762–0.803), all-cause mortality (aOR: 0.640; 95% CI: 0.612–0.670), and cardiac arrest (aOR: 0.834; 95% CI: 0.773–0.900). No differences were observed in acute HF hospitalizations, new-onset atrial fibrillation, or stroke. Conclusion SGLT2-Is are associated with improved cardiovascular outcomes in patients with AMI, including reductions in recurrent AMI, all-cause hospitalizations and mortality, and cardiac arrest. These findings emphasize the need for prospective clinical trials involving patients with AMI and other cardiovascular comorbidities, regardless of LVEF, to confirm these results.
Performance of open versus endovascular approaches in swine modeling of acute mesenteric ischemia
Banaskiewicz, Karolina , Wilken, Silvana, Stonko, David P. , Morrison, Jonathan J. , Treffalls, Rebecca, Stonko, David P , Morrison, Jonathan J , Treffalls, Rebecca N.

Vascular | April 26, 2025 | Volume: 34 | Issue: 2 | Pages: 351-356

10.1177/17085381251339240 | PMID 40285791 Get It

Objectives Traditionally, acute mesenteric ischemia studies are performed by utilizing an open superior mesenteric artery (SMA) occlusion, which is an invasive technique with potentially devastating effects. A new endovascular technique for SMA occlusion using a catheter-balloon system was designed and compared to the open SMA occlusion to test its efficacy and animal safety. Methods All animals underwent open instrumentation of the superior mesenteric vein (SMV) for blood flow monitoring. The animals were grouped into an open SMA occlusion technique group and an endovascular SMA occlusion group. The open SMA occlusion technique group involved exposure of the SMA via left medial visceral rotation with vascular clamping. In the endovascular group, an endovascular balloon was placed in the SMA and inflated to produce occlusion. Results Complete cessation of flow to the SMV was observed in the endovascular group, compared to the residual SMV flow in the open occlusion group. Following a 30-min post-occlusion period, the MAP in the endovascular group increased, compared to a decline of MAP in the open occlusion group. Conclusions This study indicates the endovascular technique provides a more potent SMA occlusion, with insignificant consequences on the overall health of the animal, in contrast to the open vascular clamping.
Pedicled Vascularized Common Peroneal Nerve Graft in Sciatic Nerve Reconstruction With Involvement of Inner Pelvic Lumbar and Sacral Nerve Roots: A Case Report and Literature Review
Wan, Rou , Sarcon, Aida K. , Aristizábal, Alejandra , Tunaboylu, Mehmet Furkan , Moran, Steven L. , Houdek, Mattew T, Houdek, Matthew T.

Microsurgery | April 26, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1002/micr.70064 | PMID 40285651 Get It

ABSTRACT Long segment losses exceeding 10 cm in the sciatic nerve are challenging in both the reconstructive techniques and optimizing sensory and motor function recovery. This case report and literature review describes our experience of using a pedicled vascularized common peroneal nerve graft to repair a 14‐cm sciatic nerve defect, involving L4 , L5 , and S1 nerve roots. Additionally, we conducted a literature review of various types of nerve autografts for large sciatic nerve defects, summarizing their characteristics and outcomes to aid clinicians in decision‐making and expected results in different scenarios. The patient, a 23‐year‐old female diagnosed with neurofibromatosis type I, underwent R0 tumor resection of the proximal left sciatic nerve due to a malignant peripheral nerve sheath tumor. She received an ipsilateral pedicled vascularized common peroneal nerve graft. The reconstruction included the L4 , L5 , and S1 nerve roots beyond the greater sciatic foramen into the inner pelvis. The patient's postoperative course was uneventful. At the 26‐month follow‐up, she showed MRC grade 4/5 strength in hamstrings with 90°knee flexion and a steady gait pattern. At the 32‐month follow‐up, she could ambulate very well with an ankle‐foot orthosis. The outcomes support the use of a pedicled vascularized common peroneal nerve graft in a single‐staged surgery to restore motor function for large sciatic nerve defects. Our literature review revealed that in cases where sural nerves are insufficient or injured for sciatic nerve reconstruction, the common peroneal nerve is a viable alternative to help patients regain functional independence.
The fetal myocardial fulcrum: echocardiographic study, functional evaluation, gross anatomy and histology
Olavarría, Alberto Sosa , Yániz, Reigosa, Peña, Martí, Peralta, Zurita, Giugni, Schenone, Ramírez, Alcedo, Peña, Martí, Ramírez, Alcedo

No container title available | April 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.174565465.58761923/v1 Get It

Objective: The fulcrum as a structure that has been described in human and mammalian hearts as ossa cordis; the aim of the present study is to demonstrate its existence in the fetal heart, using ultrasonographic techniques and macro and microscopic anatomy. Methods: Ultrasound images of the fulcrum were obtained in 240 normal fetal hearts between 26 and 37 weeks of gestation, using 2D ultrasound and TM mode in 201 cases. Speckle tracking alone was used in 58 cases to demonstrate the triphasic movements of the fulcrum. Macroscopic anatomical dissection and histological study were performed in eight fetal hearts from spontaneous abortions (20-22 weeks). Results: We demonstrated the presence of the cardiac fulcrum, on which myocardial tissue fibers are inserted as a tendon constituting a unit that serves as a pivot for cardiac contraction, resulting in a three-phase displacement of the fulcrum. Values and displacement curves were obtained as a function of gestational age, adjusted to the cubic regression model and bivariate correlation (p < 0.001). Macroscopic anatomy and histology results are presented. Conclusions: The present study demonstrated the myocardial fulcrum in the fetal heart, a structure composed of myxo-chondroid tissue, being able to be visualized by ultrasound. This structure that acts as a lever has a mixed displacement that can be quantified in terms of vertical, rotational, angular and deformation displacement. Its existence could be proved in macro and histological dissections demonstrating the anchorage of cardiac fibers at the ends of this structure.
Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria
Kulasekararaj, Austin , Dingli, David , Wilson, Koo , Wojciechowski, Piotr , Hakimi, Zalmaï , Nazir, Jameel , Czech, Barbara, Hillmen, Peter, Kulasekararaj, Austin , Dingli, David , Latour, Régis Peffault de , Szer, Jeff

European Journal of Haematology | April 26, 2025 | Volume: 115 | Issue: 2 | Pages: 125-133

10.1111/ejh.14422 | PMID 40285403 Get It

ABSTRACT Background Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired non‐malignant haematological disorder characterised by thrombosis risk, serious complications and debilitating symptoms in untreated patients. Objective This anchored indirect treatment comparison (ITC) evaluated efficacy data between proximal complement 3 inhibitor (C3i) pegcetacoplan and factor B inhibitor, iptacopan, in patients with PNH previously treated with complement 5 inhibitors (C5i; eculizumab, ravulizumab). Methods Respective pivotal studies provided patient‐level trial data for pegcetacoplan (16‐week PEGASUS [NCT03500549]) and published data for iptacopan (24‐week APPLY PNH [NCT04558918]). Differences in study design, duration and statistical methods between PEGASUS and APPLY PNH necessitated the comparative analyses to be conducted on secondary measures based on haemoglobin (Hb) levels, absolute reticulocyte count (ARC), lactate dehydrogenase (LDH) levels, and patient‐reported outcomes on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐Fatigue) scale scores. The availability of a common reference C5i treatment group in both PEGASUS and APPLY PNH studies allowed anchored ITC (Bucher method). Simulated treatment comparison (STC) assessed the robustness of the main analysis. Results Overall, baseline characteristics of the populations in the PEGASUS and APPLY PNH studies were broadly comparable. Anchored ITC showed comparable outcomes (mean difference, [95% CI]) on change‐from‐baseline to end of study for pegcetacoplan versus C5i, and iptacopan versus C5i, respectively, across endpoints: Hb level ( − 0.49 g/dL [ − 1.78, 0.80]); ARC ( – 34.41 × 10 9 /L [ − 90.02, 21.21]); LDH level ( − 115.16 U/L [ − 244.40, 14.01]); FACIT‐Fatigue score (3.57 [ − 5.60, 12.73]). Finally, the STC produced results consistent with the main Bucher analyses across all clinical endpoints and patient‐reported fatigue, providing similar point estimates and confidence intervals. Conclusion This anchored ITC, based on data from pivotal trials, did not indicate significant differences in clinical or patient‐reported outcomes between pegcetacoplan and iptacopan in PNH treatment. The findings suggest that PNH treatment decisions should also consider individualised disease‐ and patient‐related factors. Trial Registration: ClinicalTrials.gov identifier: NCT03500549.
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Bando, Hideaki , Takeda, Yuriko , Misumi, Toshihiro , Nishikawa, Tomomi, Wakabayashi, Masashi , Yamazaki, Kentaro , Oki, Eiji , Douillard, Jean‐Yves , Punt, Cornelis J. A. , Koopman, Miriam , Bokemeyer, Carsten , Lenz, Heinz‐Josef , Maehara, Yoshihiko , Gramont, Aimery de, Yoshino, Takayuki , Van Cutsem, Eric , Venook, Alan P , Lenz, Heinz-Josef , Maehara, Yoshihiko , André, Thierry , Shi, Qian , De Gramont, Aimery , Yoshino, Takayuki , Oki, Eiji , Bando, Hideaki , Cutsem, Eric Van , Venook, Alan P. , André, Thierry , Shi, Qian , Gramont, Aimery de

JNCI Cancer Spectrum | April 26, 2025 | Volume: 9 | Issue: 3 | Pages: No page available

10.1093/jncics/pkaf042 | PMID 40280867 Get It

Abstract Background Early tumor shrinkage and depth of response have emerged as potential prognostic indicators in metastatic colorectal cancer (CRC). However, their associations with overall survival, progression-free survival (PFS), and postprogression survival in patients receiving anti–epidermal growth factor receptor (EGFR) antibodies or bevacizumab remain unclear. Methods We analyzed 3219 treatment-naive patients with RAS wild-type metastatic CRC from 8 randomized studies (CRYSTAL, OPUS, PRIME, CAIRO2, CALGB80405, WJOG4407G, ATOM, PARADIGM) in the Aid and Research in Digestive Cancerology database. Early tumor shrinkage was defined as a 20% or more reduction in tumor size at 8 ± 2 weeks, whereas depth of response was assessed by maximum tumor shrinkage at nadir. Cox regression models evaluated the associations of early tumor shrinkage and depth of response with overall survival, PFS, and postprogression survival, adjusting for confounders. A 2-sided test was conducted with a significance level of .05. Results Early tumor shrinkage and depth of response substantially stratified overall survival, PFS, and postprogression survival outcomes across all treatment groups. Early tumor shrinkage positivity was associated with improved overall survival, PFS, and postprogression survival in anti-EGFR and bevacizumab-based therapies, with a trend toward better outcomes in the anti-EGFR group. The depth of response analysis revealed optimal cutoff values of 0.55 for anti-EGFR–based therapy and 0.47 for bevacizumab-based therapy to achieve a median overall survival of approximately 32 months. Conclusions Early tumor shrinkage and depth of response serve as valuable prognostic markers in RAS wild-type metastatic CRC, particularly for patients treated with anti-EGFR antibodies. These findings highlight the potential role of early tumor shrinkage and depth of response in guiding treatment strategies and improving outcomes for patients with CRC.
Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021
Huang, Xiaoquan , Ye, Sitao, Cheryala, Mahesh, Chen, Shiyao , Wang, Yichen , Tian, Li , Huang, Yu-Ting

Chinese Medical Journal | April 25, 2025 | Volume: 138 | Issue: 22 | Pages: 2947-2954

10.1097/cm9.0000000000003517 | PMID 40280878 Get It

Abstract Background: Metabolic-associated fatty liver disease (MAFLD) is a common liver disease and may become the leading cause of severe liver disease in the future. The Global Burden of Disease (GBD) study assesses MAFLD’s impact in countries and regions worldwide, providing insights into its prevalence. Methods: Prevalence data for MAFLD from 1990 to 2021 by country and region in all sex and age groups were collected from the Global Health Data Exchange. The categorization of countries and geographic areas by development was performed using the Sociodemographic Index (SDI). Results: Between 1990 and 2021, the global crude prevalence rate of MAFLD increased from 10.6% to 16.1% (beta-coefficient: 0.2%, 95% confidence interval [CI]: 0.2–0.2%, P <0.001), and the age-standardized prevalence rate was increased from 12.1% to 15.0% (beta-coefficient: 0.1%, 95% CI: 0.1–0.1%, P <0.001). In 2021, MAFLD was estimated to have affected 1.3 billion people worldwide. Significant uptrends were observed in all regions, super regions, and SDI categories. The fastest increase from 1990 to 2021 and the highest prevalence rate in 2021 were experienced by countries and territories with high–middle and middle SDI. An increase in the prevalence of MAFLD from 1990 to 2021 was demonstrated in all but six countries. Conclusions: In 2021, the number of patients affected by MAFLD was doubled compared to 1990, and the prevalence rate increased by over 50%. The burden of MAFLD, as measured by prevalence, was more prominent in countries and territories with middle SDI and in those located in North African and Middle Eastern, possibly due to changes in lifestyle in these areas over the past 30 years.